## Jonathan D Clapp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6251774/publications.pdf

Version: 2024-02-01

471509 713466 14,419 21 17 citations h-index g-index papers

21 21 21 15636 docs citations times ranked citing authors all docs

21

#	Article	IF	CITATIONS
1	Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype. Cancer, 2019, 125, 4516-4524.	4.1	33
2	Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors. Journal of Pain and Symptom Management, 2019, 57, 596-606.	1.2	31
3	The Impact of Using Different Reference Populations on Measurement of Breast Cancer-Related Cognitive Impairment Rates. Archives of Clinical Neuropsychology, 2018, 33, 956-963.	0.5	15
4	Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. Journal of Clinical Oncology, 2018, 36, 3211-3222.	1.6	112
5	Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. Journal of Health Communication, 2018, 23, 679-686.	2.4	5
6	Personality, coping, and social support as predictors of longâ€term qualityâ€ofâ€life trajectories in older breast cancer survivors: ⟨scp⟩CALGB⟨/scp⟩ protocol 369901 (⟨scp⟩A⟨/scp⟩lliance). Psycho-Oncology, 2017, 26, 1914-1921.	2.3	56
7	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research and Treatment, 2017, 163, 391-398.	2.5	16
8	Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Research and Treatment, 2017, 164, 107-117.	2.5	68
9	Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Research and Treatment, 2017, 165, 677-686.	2.5	17
10	Longâ€ŧerm trajectories of selfâ€reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer, 2016, 122, 3555-3563.	4.1	71
11	Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?. Journal of Clinical Oncology, 2014, 32, 1909-1918.	1.6	129
12	Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal of Clinical Oncology, 2014, 32, 2318-2327.	1.6	80
13	Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. Journal of Cancer Survivorship, 2014, 8, 627-637.	2.9	35
14	Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. Journal of the National Cancer Institute, 2012, 104, 125-132.	6.3	947
15	Effect of Screening on Ovarian Cancer Mortality. JAMA - Journal of the American Medical Association, 2011, 305, 2295.	7.4	1,080
16	Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine, 2011, 365, 395-409.	27.0	8,392
17	Cumulative Incidence of False-Positive Test Results in Lung Cancer Screening. Annals of Internal Medicine, 2010, 152, 505.	3.9	139
18	Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. Journal of the National Cancer Institute, 2010, 102, 1771-1779.	6.3	283

#	Article	IF	CITATIONS
19	Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening. Annals of Family Medicine, 2009, 7, 212-222.	1.9	127
20	Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine, 2009, 360, 1310-1319.	27.0	2,592
21	Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial. Journal of the National Cancer Institute, 2005, 97, 433-438.	6.3	191